Johnson & Johnson’s “Generation Fine” campaign highlights persistent MDD treatment gaps and encourages patients to aim for depression remission beyond feeling “fine.”
Written By: Dr. Preethi Putti, PharmD
Reviewed By: Pharmacally Editorial Team
Johnson & Johnson has expanded its “Generation Fine” campaign in 2026 following the initiative’s global launch in late 2025, aiming to encourage people living with depression to expect more from treatment and work toward remission rather than simply feeling “fine.” The campaign was introduced after a multinational survey revealed major gaps in how people living with major depressive disorder (MDD) view recovery and antidepressant treatment outcomes.
Campaign Focuses on Moving Beyond “Fine”
The initiative challenges the idea that depression management means settling for partial improvement. Through patient stories, educational resources, and expert perspectives, the campaign encourages more open conversations between patients and healthcare providers about persistent symptoms, remission goals, and treatment expectations.
Developed in collaboration with Mental Health America, the campaign also highlights the emotional and social burden many patients continue to experience despite ongoing treatment.
MDD Remains a Major Global Health Burden
MDD is one of the leading causes of disability worldwide, affecting an estimated 332 million people globally, or roughly 5 per cent of adults. In the United States alone, around 22 million adults are estimated to live with the condition.
MDD is a complex and highly variable psychiatric disorder that affects multiple brain regions and may present through as many as 256 different symptom combinations. While oral antidepressants benefit many patients, studies suggest that nearly two-thirds of people with MDD continue to experience depressive symptoms during treatment, highlighting ongoing MDD treatment gaps and concerns surrounding antidepressant remission rates.
Treatment strategies for MDD may include psychotherapy, lifestyle interventions, medication adjustments, and newer therapeutic approaches depending on symptom severity and individual patient response.
Global Survey Highlights Persistent Treatment Challenges
The “Generation Fine” survey was conducted online by Wakefield Research between August 6 and 17, 2025, across seven countries including the United States, Brazil, Canada, China, Germany, Italy, and Spain. The survey included 850 adults currently managing MDD with oral antidepressants and 800 healthcare providers treating patients with MDD.
The findings revealed that nearly four in five people living with MDD do not believe antidepressants can help them fully recover. Many participants reported persistent symptoms affecting work performance, relationships, motivation, and daily functioning even while receiving treatment.
Nearly 90 per cent of respondents said depression symptoms negatively affected their ability to function at work, while more than half reported isolating themselves socially more often because of their condition.
The survey also highlighted communication gaps between patients and healthcare providers. Many participants said they struggled to discuss persistent symptoms because they lacked the energy to initiate conversations or believed their providers had limited additional treatment options to offer.
Healthcare providers participating in the survey also acknowledged that patients may underreport ongoing symptoms during appointments, potentially making it more difficult to identify patients who are not achieving remission.
Experts Emphasise Need for Individualised Care
Mental health advocates say the findings reflect the complexity of depression and the limitations of standard treatment approaches.
“Depression doesn’t look the same for everyone. Still, it is often treated with the same one-size-fits-all approach,” said Jessica Jackson, Ph.D., Vice President of Alliance Development at Mental Health America.
“These findings reinforce what patients have been telling us for years: far too many continue to struggle despite being on treatment,” said Peter Fang, Worldwide Vice President, Neuroscience, Global Commercial Strategy Organisation, Johnson & Johnson.
Psychiatrist Jessi Gold also stressed that patients should not lose hope if initial treatments fail to fully address symptoms, adding that people living with depression deserve to feel better than simply “fine.”
Public Figures Share Personal Experiences With Depression
As part of the campaign, former NFL player Kyle Long shared his personal experience living with depression. He spoke about the importance of honesty, support systems, and seeking professional medical help rather than attempting to manage depression alone.
The campaign uses personal stories to reduce stigma and highlight how common and often invisible depression can be, including among high-profile public figures.
Encouraging Conversations Around Depression Remission
Through the “Generation Fine” initiative, Johnson & Johnson hopes to empower people living with depression to speak more openly with healthcare providers about persistent symptoms and treatment expectations while encouraging a broader focus on remission rather than partial symptom improvement.
More information about depression support resources and treatment discussions is available through Mental Health America and qualified healthcare professionals.
References
About the Writer
Dr.Preethi Putti, PharmD (LinkedIn)is a pharmaceutical researcher with experience in healthcare and pharmaceutical market research and competitive intelligence. She specializes in analyzing drug pipelines, clinical data, and industry trends and translating complex scientific data into clear and structured medical content. Strong foundation in clinical research, data interpretation, and evidence-based healthcare analysis. Committed to advancing a global career in clinical research and healthcare innovation.